http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20130054702-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17c6c7da627b7bead7208250127b52c2 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2011-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_841c44d073d83020d0fd8a1d859c1586 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30fad18a025eee292d4ffdf8e48c1566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a4a904de94fe09061de36d54c7c57fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac118b3b9367c2fc18d1c3911fe6e77b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4963732a5df681ba4cadc112053b339e |
| publicationDate | 2013-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20130054702-A |
| titleOfInvention | In Vitro Amplification of Bone Marrow-derived Immune Regulatory Cells and Immune Regulatory Ｂ Lymphocytes by Activation of the JPPCR19 Pathway |
| abstract | The present invention provides a method for screening a therapeutic agent for a GPCR19-associated disease. The present invention also provides a method for analyzing the efficacy of GPCR19 agonists. The present invention also provides a Myeloid-derived suppressor cell (MDSC) formed by in vivo physiological activity modulator and GPCR19 agonist treatment, having Gr-1 + CD11b + surface morphology and having anti-inflammatory activity. In addition, the present invention provides immune regulatory B cells (regulatory B cells) formed by treatment with physiological activity in vivo and GPCR19 agonists or by H-MDSC treatment and having B220 + surface expression type and having anti-inflammatory activity do. The present invention also provides an anti-inflammatory pharmaceutical composition comprising H-MDSC or B HM cells as an active ingredient. The present invention also provides an anticancer pharmaceutical composition comprising H-MDSC, 48H B H or B HM cells as an active ingredient. The present invention also provides an anti-inflammatory pharmaceutical composition comprising a GPCR19 agonist formulated for the purpose of amplifying H-MDSC or 48H B H cells in vivo. According to the present invention, administration of sodium taurodeoxycholate (HY-2191) in mice in which inflammation was induced by the administration of lipopolysaccharide (LPS) increased the number of H-MDSC cells and increased H-MDSC Has a significant treatment effect on sepsis. According to the present invention, administration of sodium taurodeoxycholate (HY2191) in mice in which inflammation is induced by the administration of lipopolysaccharide (LPS) increases the number of immunoregulatory B cells (48h B H cells) 48h B H cells showed significant sepsis treatment effect. According to the present invention, the number of B HM cells is increased by the administration of H-MDSC in inflammation-induced mice by administration of lipopolysaccharide (LPS), and the increased B HM The cells show significant sepsis treatment effects. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9855283-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150024805-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9629854-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104853759-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015030328-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180111284-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015037764-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101588582-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104853759-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017014561-A1 |
| priorityDate | 2011-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 627.